Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer
Susana R�os, Alan J. Wright, Paula D’Santos, De‐En Hu, Richard L. Hesketh, Yaniv Lubling, Dimitra Georgopoulou, Giulia Lerda, Dominique‐Laurent Couturier, Pedram Razavi, Rapahel Pelossof, Ankita Sati Batra, Elizabeth Mannion, David Y. Lewis, Alistair Martin, Richard D. Baird, Mafalda Oliveira, Leonora W. de Boo, Sabine C. Linn, Maurizio Scaltriti, Oscar M. Rueda, Alejandra Bruna, Carlos Caldas, Kevin M. Brindle
Abstract
F]fluorodeoxyglucose. Rapid assessment of treatment response in breast cancer using this imaging method could help identify patients that benefit from PI3Kα inhibition and design drug combinations to counteract the emergence of resistance.
Topics & Concepts
FOXM1Breast cancerCancer researchPI3K/AKT/mTOR pathwayCancerBiologyMedicineCell biologySignal transductionInternal medicineCell cycleFOXO transcription factor regulationMetabolism, Diabetes, and CancerGenomics, phytochemicals, and oxidative stress